New method for the preparation of 1,5-bis(4-hydroxy-3-metoxy-phenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties
申请人:Suarez Agustin Quincoces Jose
公开号:US20060128997A1
公开(公告)日:2006-06-15
This patent of invention reports the method for the preparation of 1,5-bis(4-hydroxy-3-methoxyphenyl)-penta-1,4-dien-3-one and derivatives with antitumoral properties: the sample denominated 37 compound was obtained with high yield and purity with ultrasonic technique presenting cytostatic activity (growth inhibition) in the concentrations evaluated and cytotoxic activity (cellular death) from the concentration of 0.25 mg/mL against nine different types of human cancer cell lines. This compound has a LD50, equals to 8.54 g/Kg. That means this product can be considered itself as practically nontoxic. Doxorubicin, anticarcinogen medicine used as reference in all these tests, is a product extremely toxic (LD50 of 20 mg/Kg) and it does not inhibit the growth of Mama NCI-ADR cell line (the one that expresses the phenotype of resistance against multiple drugs), therefore our product presented a strong cytostatic activity. Other derivatives also presented a strong cytostatic activity, specially the one denominated EHB1 compound.
本发明专利介绍了具有抗肿瘤特性的 1,5-双(4-羟基-3-甲氧基苯基)-1,4-戊二烯-3-酮及其衍生物的制备方法:通过超声波技术获得的 37 号化合物样品产量高、纯度高,在评估浓度下具有细胞抑制活性(生长抑制),在 0.25 毫克/毫升浓度下对九种不同类型的人类癌细胞株具有细胞毒性活性(细胞死亡)。该化合物的半数致死剂量为 8.54 克/千克。这意味着该产品本身实际上是无毒的。在所有这些测试中用作参考的抗癌药物多柔比星是一种毒性极强的产品(半数致死剂量为 20 毫克/千克),它不能抑制 Mama NCI-ADR 细胞系(表达对多种药物耐药表型的细胞系)的生长,因此我们的产品具有很强的细胞抑制活性。其他衍生物也具有很强的细胞抑制活性,特别是名为 EHB1 的化合物。